QC
CBIO icon

Quadrature Capital’s Crescent Biopharma CBIO Stock Holding History

Quadrature Capital’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$346K Sell
19,227
-1,690
-8% -$33K ﹤0.01% 1147
2026
Q1 		$384K Buy
20,917
+7,671
+58% +$88.1K ﹤0.01% 884
2025
Q4 		$157K Buy
+13,246
New +$169K ﹤0.01% 1019

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Quadrature Capital's CBIO Position: Q2 2026 in Review

Quadrature Capital reduced its Crescent Biopharma (CBIO) stake by 8.1% in Q2 2026, selling an estimated $33K and leaving 19,227 shares worth $346K. The position accounts for ﹤0.01% of the portfolio, ranked #1147.

Quadrature Capital first reported a position in CBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $384K in Q1 2026. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Quadrature Capital held 19,227 shares of Crescent Biopharma worth $346K as of Q2 2026.
  • Quadrature Capital sold 1,690 Crescent Biopharma shares in Q2 2026, an estimated $33K.
  • Crescent Biopharma made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1147 holding.
  • Quadrature Capital first reported a position in Crescent Biopharma in Q4 2025 and has held it in 3 quarters since.
  • Quadrature Capital's Crescent Biopharma position peaked at $384K in Q1 2026.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.